Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 1
2009 1
2010 2
2011 1
2012 1
2013 3
2014 2
2015 1
2016 1
2018 1
2019 2
2020 7
2021 9
2022 11
2023 14
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Switching Biological Therapies in Severe Asthma.
Scioscia G, Nolasco S, Campisi R, Quarato CMI, Caruso C, Pelaia C, Portacci A, Crimi C. Scioscia G, et al. Among authors: nolasco s. Int J Mol Sci. 2023 May 31;24(11):9563. doi: 10.3390/ijms24119563. Int J Mol Sci. 2023. PMID: 37298514 Free PMC article. Review.
Tezepelumab for asthma.
Nolasco S, Pelaia C, Scioscia G, Campisi R, Crimi C. Nolasco S, et al. Drugs Today (Barc). 2022 Dec;58(12):591-603. doi: 10.1358/dot.2022.58.12.3449205. Drugs Today (Barc). 2022. PMID: 36651067 Review.
Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
Nolasco S, Portacci A, Campisi R, Buonamico E, Pelaia C, Benfante A, Triggiani M, Spadaro G, Caiaffa MF, Scioscia G, Detoraki A, Valenti G, Papia F, Tomasello A, Crimi N, Scichilone N, Pelaia G, Carpagnano GE, Crimi C. Nolasco S, et al. Front Immunol. 2023 Jun 30;14:1204444. doi: 10.3389/fimmu.2023.1204444. eCollection 2023. Front Immunol. 2023. PMID: 37457743 Free PMC article.
Real-world characteristics of "super-responders" to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.
Portacci A, Campisi R, Buonamico E, Nolasco S, Pelaia C, Crimi N, Benfante A, Triggiani M, Spadaro G, Caiaffa MF, Scioscia G, Detoraki A, Valenti G, Papia F, Tomasello A, Scichilone N, Pelaia G, Crimi C, Carpagnano GE. Portacci A, et al. Among authors: nolasco s. ERJ Open Res. 2023 Oct 30;9(5):00419-2023. doi: 10.1183/23120541.00419-2023. eCollection 2023 Sep. ERJ Open Res. 2023. PMID: 37908397 Free PMC article.
Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study.
Bettiol A, Urban ML, Padoan R, Groh M, Lopalco G, Egan A, Cottin V, Fraticelli P, Crimi C, Del Giacco S, Losappio L, Moi L, Cinetto F, Caminati M, Novikov P, Berti A, Cameli P, Cathébras P, Coppola A, Durel CA, Folci M, Lo Gullo A, Lombardi C, Monti S, Parronchi P, Rivera CM, Solans R, Vacca A, Espígol-Frigolé G, Guarnieri G, Bianchi FC, Marchi MR, Tcherakian C, Kahn JE, Iannone F, Venerito V, Desaintjean C, Moroncini G, Nolasco S, Costanzo GAML, Schroeder JW, Ribi C, Tesi M, Gelain E, Mattioli I, Bello F, Jayne D, Prisco D, Vaglio A, Emmi G; European EGPA Study Group. Bettiol A, et al. Among authors: nolasco s. Lancet Rheumatol. 2023 Dec;5(12):e707-e715. doi: 10.1016/S2665-9913(23)00243-6. Epub 2023 Nov 6. Lancet Rheumatol. 2023. PMID: 38251561
Features of severe asthma response to anti-IL5/IL5r therapies: identikit of clinical remission.
Carpagnano GE, Portacci A, Nolasco S, Detoraki A, Vatrella A, Calabrese C, Pelaia C, Montagnolo F, Scioscia G, Valenti G, D'Amato M, Caiaffa MF, Triggiani M, Scichilone N, Crimi C. Carpagnano GE, et al. Among authors: nolasco s. Front Immunol. 2024 Jan 23;15:1343362. doi: 10.3389/fimmu.2024.1343362. eCollection 2024. Front Immunol. 2024. PMID: 38327518 Free PMC article.
62 results